NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye injection could rival standard treatment for blinding disease
Disease control Not yet recruitingThis study tests a new drug called QL1207H against an approved treatment (Eylea) for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, then every 16 weeks…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New eye drug trial aims to restore sight in macular degeneration patients
Disease control Not yet recruitingThis study will test a medicine called faricimab in 50 people with a type of wet age-related macular degeneration (nAMD) that has not been treated before. Participants will receive four initial eye injections, then more as needed. The goal is to see if the treatment improves visi…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Wet AMD patients needed for Long-Term safety check of eye implant
Disease control Not yet recruitingThis study looks at the long-term safety of an eye implant (OTX-TKI) for people with wet age-related macular degeneration. Participants must have already finished a 2-year study of the same implant. The goal is to track side effects and vision changes over about 3 more years.
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New eye injection shows promise for blinding disease
Disease control Not yet recruitingThis early-stage study tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 48 participants will receive either a single or multiple doses to check safety and how well it works.…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Could a cotton swab replace the metal speculum for eye injections?
Symptom relief Not yet recruitingThis study tests whether using a cotton-tipped applicator to hold the eyelid open during eye injections is less painful and faster than the standard metal speculum. About 120 adults with certain eye conditions will take part. The goal is to improve comfort and satisfaction withou…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: NA • Sponsor: Jakkrit Juhong • Aim: Symptom relief
Last updated May 22, 2026 13:51 UTC